Arcadia Consumer Healthcare

Arcadia acquires and operates consumer health brands in the over-the-counter, personal care, and vitamin, mineral and supplement categories. The platform targets clinically efficacious, premium-positioned products where quality and therapeutic credibility support repeat purchase. The firm emphasizes operational scale and high-growth brand building over financial engineering or rapid asset flipping.

The firm does not publicly disclose its management team, board, or investment committee structure. A contact email on the firm's website references Kramer Labs at Emerson Group, suggesting a connection to the established contract sales and marketing organization Emerson Group, though the precise operating relationship remains unconfirmed in public filings.

Arcadia presents as a holding company or permanent capital platform rather than a close-ended private equity fund. It does not publish fundraising timelines, vehicle structures, or investor reporting. Its model appears oriented toward indefinite hold periods for operating businesses, with centralized brand management and product innovation capabilities supporting portfolio companies.

The firm's public disclosures describe only direct ownership and operation of consumer healthcare brands. There is no publicly available information indicating participation in third-party fund commitments, co-investment vehicles, or syndicated deals alongside external general partners.

Specific portfolio company names are not disclosed on the firm's public website. The firm references a suite of premium brands across the OTC, personal care, and VMS categories. A contact reference to Kramer Laboratories may represent a legacy or current portfolio asset, though this linkage is not explicitly confirmed in available materials.